Results 41 to 50 of about 10,198,101 (175)

Talimogen laherparepwek (T-VEC) — nowa terapia czerniaków skóry zmodyfikowanym genetycznie wirusem onkolitycznym [PDF]

, 2016
Talimogene laherparepvec (T-VEC) is the first (approved recently in the European Union) oncolytic immunotherapy which demonstrated therapeutic benefit for cutaneous melanoma in a phase III clinical trial.
Rutkowski, Piotr, Zdzienicki, Marcin
core   +1 more source

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

OncoImmunology, 2018
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi   +14 more
doaj   +1 more source

Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease

Annals of Clinical and Translational Neurology, 2022
Objective Endothelial dysfunction is an early and prevalent pathology in Alzheimer disease (AD). We here investigate the value of vascular endothelial‐cadherin (VEC) as a cerebrospinal fluid (CSF) marker of endothelial injury in preclinical AD.
Rawan Tarawneh, Rachel S. Kasper, Jessie Sanford, Chia‐Ling Phuah, Jason Hassenstab, Carlos Cruchaga   +5 more
doaj   +1 more source

Madelung mechanics and superoscillations

New Journal of Physics
In single-particle Madelung mechanics, the single-particle quantum state $\Psi(\vec{x},t) = R(\vec{x},t) e^{iS(\vec{x},t)/\hbar}$ is interpreted as comprising an entire conserved fluid of classical point particles, with local density $R(\vec{x},t)^2$ and
Mordecai Waegell
doaj   +1 more source

Uremic serum induces prothrombotic changes in venous endothelial cells and inflammatory changes in aortic endothelial cells

Renal Failure, 2021
Background Uremia induces various pathologic changes in the endothelium. However, there is limited information about the differences of these effects in endothelial cells originating from different parts of the vascular tree. Methods The effect of uremic
Patrycja Sosińska-Zawierucha, Andrzej Bręborowicz   +1 more
doaj   +1 more source

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers

Frontiers in Oncology, 2022
The need for efficacious and non-toxic cancer therapies is paramount. Oncolytic viruses (OVs) are showing great promise and are introducing new possibilities in cancer treatment with their ability to selectively infect tumor cells and trigger antitumor ...
Hayle Scanlan, Zachary Coffman, Jeffrey Bettencourt, Timothy Shipley, Debra E. Bramblett   +4 more
doaj   +1 more source

OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models

Journal for ImmunoTherapy of Cancer, 2023
Background Checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have demonstrated clinical efficacy in advanced melanoma, but only a subset ...
Jinghui Zhan, Petia Mitchell, Juan Estrada, Jonathan Werner, Jason DeVoss, Pedro J Beltran, Jing Qing, Keegan S Cooke   +7 more
doaj   +1 more source

593 Tumoral melanosis mimicking residual melanoma After T-VEC treatment

Regular and young investigator award abstracts, 2020
Background Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma based on its durable efficacy and safety profile. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. [figure 1,2] Assessment of treatment response in those
Song Park, Ata Moshiri, Rouba Hadi, Austin Green, Jennifer Gardner, Coley Doolittle-Amieva   +5 more
openaire   +1 more source

High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a) [PDF]

International Journal of Cancer, 2019
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%.
Viola Franke, Danique M.S. Berger, W. Martin C. Klop, Bernies van der Hiel, Bart A. van de Wiel, Sylvia ter Meulen, Michel W.J.M. Wouters, Winan J. van Houdt, Alexander C.J. van Akkooi   +8 more
openaire   +2 more sources

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Journal for ImmunoTherapy of Cancer, 2018
Background Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma.
Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero, Brian Gastman   +8 more
doaj   +1 more source